

David Edmund Szymkowski

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6670968/publications.pdf>

Version: 2024-02-01

56
papers

3,371
citations

185998

28
h-index

149479

56
g-index

61
all docs

61
docs citations

61
times ranked

4216
citing authors

#	ARTICLE	IF	CITATIONS
1	Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease. <i>Journal of Neuroscience</i> , 2006, 26, 9365-9375.	1.7	331
2	Inactivation of TNF Signaling by Rationally Designed Dominant-Negative TNF Variants. <i>Science</i> , 2003, 301, 1895-1898.	6.0	222
3	MUC17, a Novel Membrane-Tethered Mucin. <i>Biochemical and Biophysical Research Communications</i> , 2002, 291, 466-475.	1.0	187
4	Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination. <i>Brain</i> , 2011, 134, 2736-2754.	3.7	174
5	Cloning of the Amino-terminal and 5' Flanking Region of the Human MUC5AC Mucin Gene and Transcriptional Up-regulation by Bacterial Exoproducts. <i>Journal of Biological Chemistry</i> , 1998, 273, 6812-6820.	1.6	160
6	Dominant-Negative Inhibitors of Soluble TNF Attenuate Experimental Arthritis without Suppressing Innate Immunity to Infection. <i>Journal of Immunology</i> , 2007, 179, 1872-1883.	0.4	148
7	Antibody-Mediated Coengagement of Fc γ RIIb and B Cell Receptor Complex Suppresses Humoral Immunity in Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2011, 186, 4223-4233.	0.4	142
8	Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and Fc γ RIIb with Fc-engineered antibodies. <i>Molecular Immunology</i> , 2008, 45, 3926-3933.	1.0	128
9	Soluble TNF Mediates the Transition from Pulmonary Inflammation to Fibrosis. <i>PLoS ONE</i> , 2006, 1, e108.	1.1	116
10	Oligodendroglial TNFR2 Mediates Membrane TNF-Dependent Repair in Experimental Autoimmune Encephalomyelitis by Promoting Oligodendrocyte Differentiation and Remyelination. <i>Journal of Neuroscience</i> , 2016, 36, 5128-5143.	1.7	113
11	Phorbol 12-Myristate 13-Acetate Up-regulates the Transcription of MUC2 Intestinal Mucin via Ras, ERK, and NF- κ B. <i>Journal of Biological Chemistry</i> , 2002, 277, 32624-32631.	1.6	93
12	Hippocampal TNF Signaling Contributes to Seizure Generation in an Infection-Induced Mouse Model of Limbic Epilepsy. <i>ENeuro</i> , 2017, 4, ENEURO.0105-17.2017.	0.9	88
13	Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor- κ B. <i>Brain</i> , 2011, 134, 2722-2735.	3.7	85
14	Reduction of total IgE by targeted coengagement of IgE B-cell receptor and Fc γ RIIb with Fc-engineered antibody. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 1102-1115.	1.5	81
15	Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia. <i>Journal of Neuroinflammation</i> , 2014, 11, 203.	3.1	79
16	Therapeutic inhibition of soluble brain TNF promotes remyelination by increasing myelin phagocytosis by microglia. <i>JCI Insight</i> , 2017, 2, .	2.3	72
17	Transmembrane TNF is sufficient for articular inflammation and hypernociception in a mouse model of gout. <i>European Journal of Immunology</i> , 2016, 46, 204-211.	1.6	67
18	Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15. <i>Blood</i> , 2010, 116, 575-583.	0.6	63

#	ARTICLE	IF	CITATIONS
19	Central but not systemic administration of XPro1595 is therapeutic following moderate spinal cord injury in mice. <i>Journal of Neuroinflammation</i> , 2014, 11, 159.	3.1	62
20	Harnessing Fc receptor biology in the design of therapeutic antibodies. <i>Current Opinion in Immunology</i> , 2016, 40, 78-87.	2.4	59
21	Soluble TNF, but not membrane TNF, is critical in LPS-induced hepatitis. <i>Journal of Hepatology</i> , 2010, 53, 1059-1068.	1.8	56
22	Neutralization of Membrane TNF, but Not Soluble TNF, Is Crucial for the Treatment of Experimental Colitis. <i>Inflammatory Bowel Diseases</i> , 2013, 19, 246-253.	0.9	56
23	Developing antisense oligonucleotides from the laboratory to clinical trials. <i>Drug Discovery Today</i> , 1996, 1, 415-428.	3.2	51
24	Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti-CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fcγ3 Receptor IIb Inhibitory Receptor. <i>Arthritis and Rheumatology</i> , 2014, 66, 1153-1164.	2.9	51
25	Dominant-Negative Tumor Necrosis Factor Protects from <i>Mycobacterium bovis</i> Bacillus Calmette-Guérin (BCG) and Endotoxin-Induced Liver Injury without Compromising Host Immunity to BCG and <i>Mycobacterium tuberculosis</i> . <i>Journal of Infectious Diseases</i> , 2009, 199, 1053-1063.	1.9	48
26	Inhibition of Soluble Tumor Necrosis Factor Ameliorates Synaptic Alterations and Ca ²⁺ Dysregulation in Aged Rats. <i>PLoS ONE</i> , 2012, 7, e38170.	1.1	47
27	Roles of Soluble and Membrane TNF and Related Ligands in Mycobacterial Infections: Effects of Selective and Non-selective TNF Inhibitors During Infection. <i>Advances in Experimental Medicine and Biology</i> , 2011, 691, 187-201.	0.8	29
28	An XPG DNA repair defect causing mutagen hypersensitivity in mouse leukemia L1210 cells. <i>Molecular and Cellular Biology</i> , 1995, 15, 290-297.	1.1	28
29	Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to Fcγ3RIIb. <i>Immunology Letters</i> , 2012, 143, 34-43.	1.1	28
30	Suppression of innate and adaptive B cell activation pathways by antibody coengagement of Fcγ3RIIb and CD19. <i>MAbs</i> , 2014, 6, 991-999.	2.6	28
31	Non-specific antiviral activity of antisense molecules targeted to the E1 region of human papillomavirus. <i>Antiviral Research</i> , 2000, 48, 187-196.	1.9	27
32	Immunotherapy with Long-Lived Anti-CD123 – Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD123+ Cells in Monkeys: A Potential Therapy for Acute Myelogenous Leukemia. <i>Blood</i> , 2014, 124, 2316-2316.	0.6	27
33	Tuning T Cell Affinity Improves Efficacy and Safety of Anti-CD38 – Anti-CD3 Bispecific Antibodies in Monkeys - a Potential Therapy for Multiple Myeloma. <i>Blood</i> , 2015, 126, 1798-1798.	0.6	26
34	Allergic Lung Inflammation Is Mediated by Soluble Tumor Necrosis Factor (TNF) and Attenuated by Dominant-Negative TNF Biologics. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2011, 45, 731-739.	1.4	25
35	Tumour necrosis factor-mediated macrophage activation in the target organ is critical for clinical manifestation of uveitis. <i>Clinical and Experimental Immunology</i> , 2012, 168, 165-177.	1.1	25
36	Topical Administration of a Soluble TNF Inhibitor Reduces Infarct Volume After Focal Cerebral Ischemia in Mice. <i>Frontiers in Neuroscience</i> , 2019, 13, 781.	1.4	25

#	ARTICLE	IF	CITATIONS
37	Immune suppression in cynomolgus monkeys by XPro9523. MAbs, 2013, 5, 384-396.	2.6	23
38	Creating the next generation of protein therapeutics through rational drug design. Current Opinion in Drug Discovery & Development, 2005, 8, 590-600.	1.9	21
39	Altered Expression of Oligodendrocyte and Neuronal Marker Genes Predicts the Clinical Onset of Autoimmune Encephalomyelitis and Indicates the Effectiveness of Multiple Sclerosis-Directed Therapeutics. Journal of Immunology, 2014, 192, 4122-4133.	0.4	18
40	Identification and characterization of a Dictyostelium discoideum ribosomal protein gene. Nucleic Acids Research, 1990, 18, 4695-4701.	6.5	17
41	Electron Microscopy of DNA Excision Repair Patches Produced by Human Cell Extracts. Journal of Molecular Biology, 1993, 231, 251-260.	2.0	16
42	ADictyostelium discoideum cDNA coding for a protein with homology to the rat ribosomal protein L7. Nucleic Acids Research, 1989, 17, 5393-5393.	6.5	15
43	Immunotherapy with Long-Lived Anti-CD38 Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human Myeloma Cell Lines and CD38+ Cells in Monkeys: A Potential Therapy for Multiple Myeloma. Blood, 2014, 124, 4727-4727.	0.6	14
44	Immunotherapy with Long-Lived Anti-CD20 Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human B Cell Lines and of Circulating and Lymphoid B Cells in Monkeys: A Potential Therapy for B Cell Lymphomas and Leukemias. Blood, 2014, 124, 3111-3111.	0.6	12
45	Too many targets, not enough target validation. Drug Discovery Today, 2001, 6, 397.	3.2	11
46	Inhibition of TNF reduces mechanical orofacial hyperalgesia induced by Complete Freund's Adjuvant by a TRPV1-dependent mechanism in mice. Pharmacological Reports, 2017, 69, 1380-1385.	1.5	11
47	Inhibition of B cell activation following in vivo co-engagement of B cell antigen receptor and Fcγ3R1b in non-autoimmune-prone and SLE-prone mice. Journal of Translational Autoimmunity, 2021, 4, 100075.	2.0	9
48	Trypanosoma brucei growth control by TNF in mammalian host is independent of the soluble form of the cytokine. Scientific Reports, 2017, 7, 6165.	1.6	8
49	Rational optimization of proteins as drugs: a new era of medicinal biology?. Drug Discovery Today, 2004, 9, 381-383.	3.2	6
50	Accelerated Clearance and Degradation of Cell-Free HIV by Neutralizing Antibodies Occurs via Fcγ3R1b on Liver Sinusoidal Endothelial Cells by Endocytosis. Journal of Immunology, 2021, 206, 1284-1296.	0.4	6
51	Target validation joins the pharma fold. Targets, 2003, 2, 8-9.	0.3	4
52	Timely lessons for target-based discovery of anti-inflammatory drugs. Drug Discovery Today, 2005, 10, 14-17.	3.2	1
53	Suppression Of IgE Production By XmAb7195, An Fc-Engineered Antibody That Specifically Coengages Inhibitory Receptor FcγR1b With IgE-BCR. , 2011, , .		0
54	Central but not peripheral administration of XPro1595 is therapeutic following moderate spinal cord injury in mice. Journal of Neuroimmunology, 2014, 275, 114-115.	1.1	0

#	ARTICLE	IF	CITATIONS
55	A1.84â€¦Switching off B cells by Fc-engineered anti-CD19 antibody (XmAb5871). Annals of the Rheumatic Diseases, 2014, 73, A37.1-A37.	0.5	0
56	Hypersensitivity to Cisplatin in Mouse Leukemia L1210/0 Cells: An XPG DNA Repair Defect. , 1996, , 317-326.		0